EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparison of Dual-Luciferase® Reporter Assay and a Stably Transfected NF-κB Reporter Cell Line for Detecting TNF-α and X-Ray-Induced Pathway Activation

Sebastian Feles, Sebastian Diegeler, Bernd Henschenmacher, Christa Baumstark-Khan, Christine Elisabeth Hellweg

Methods and Protocols · 2026-11-09 · 9 (6) · 164

DOI: 10.3390/mps9060164 ↗
AbstractBibliografische Angaben

Abstract

The transcription factor nuclear factor kappa B (NF-κB) is a central regulator of inflammatory and genotoxic stress responses and is involved in immune function and disease pathogenesis. Reporter assays are widely used to quantify NF-κB activation, yet systematic benchmarks between transient dual-luciferase and stable fluorescent formats under harmonized conditions are lacking. We compared a transient Dual-Luciferase® Reporter (DLR™) assay in HEK293 cells with the stably transfected HEK-pNF-κB-d2EGFP/Neo L2 cell line using recombinant TNF-α and X-rays as stimuli. Dynamic range, limit of detection (LOD), signal-to-noise ratio (S/N), and half-maximal effective concentrations and doses (EC50, ED50) were derived from four-parameter logistic modeling. The HEK-pNF-κB-d2EGFP/Neo L2 line showed higher sensitivity to TNF-α (EC50 = 0.31 ng/mL) than the DLR™ assay (1.2–2.0 ng/mL) and a lower LOD, whereas the DLR™ assay provided better temporal resolution, revealing assay-specific signal decline attributable to reporter stability and readout kinetics. For X-ray exposure, both systems showed comparable potency (EC50 ≈ 5–8 Gy), while the stable cell line maintained superior S/N. Both reporter systems support high-throughput and mechanistic applications: the DLR™ assay offers versatility across cell types, while the HEK-pNF-κB-d2EGFP/Neo L2 line provides higher sensitivity, dynamic range, and single-cell resolution.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →